Evidence map›Paper›PMID 37931692›Full record

ArticleCellular signalling2024

TGFβ1-driven SMAD2/3 phosphorylation and myofibroblast emergence are fully dependent on the TGFβ1 pre-activation of MAPKs and controlled by maternal leucine zipper kinase.

Zheng Wang, Nileyma Castro, Audrey M Bernstein, J Mario Wolosin

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Targeting TGF-β: a promising strategy for cancer therapy.Medical oncology (Northwood, London, England) · 2025
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Zheng WangDepartment of Ophthalmology and Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nileyma CastroDepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, New York, USA.
Audrey M BernsteinDepartment of Ophthalmology and Visual Sciences, SUNY Upstate Medical University, Syracuse, New York, USA; New York VA Health Care, Medical Center, Syracuse, VA, USA.
J Mario WolosinDepartment of Ophthalmology and Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: jmario.wolosin@mssm.edu.
Icahn School of Medicine at Mount Sinai · USSUNY Upstate Medical University · USSyracuse VA Medical Center · US

Funding

THE UBIQUITIN PATHWAY IN CORNEAL SCARRINGR01EY024942 · NEI · UPSTATE MEDICAL UNIVERSITY · PI AUDREY M BERNSTEIN · 2015 to 2026
$3.1M
A single dose anti-scarring therapeutic for the corneaR44EY035188 · NEI · DUB THERAPEUTICS INC. · PI WILLIAMS, TERE M. · 2023 to 2024
$1.8M
ROS and MAPK signal cascades in corneal myofibroblast genesisR01EY029279 · NEI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WOLOSIN, JOSE MARIO · 2018 to 2021
$1.7M
Cellular Dysfunction in Exfoliation GlaucomaR01EY030567 · NEI · UPSTATE MEDICAL UNIVERSITY · PI BERNSTEIN, AUDREY M, WOLOSIN, JOSE MARIO · 2020 to 2023
$1.6M
A Self-Delivery siRNA for Promoting Regenerative Healing in the EyeI01BX005360 · VA · SYRACUSE VA MEDICAL CENTER · PI BERNSTEIN, AUDREY M · 2021 to 2024
–
BLRD VA I01 BX005360NEI NIH HHS R01 EY024942NEI NIH HHS R01 EY029279NEI NIH HHS R01 EY030567NEI NIH HHS R44 EY035188
6 · The paper itself

Abstract

Following wounding, endogenously secreted TGFβs drive resident and bone marrow-derived cells to convert into α-smooth actin (SMA)-rich, contractile myofibroblasts. The TGFβ effect is initiated by the phosphorylation of SMADs 2 and 3 (SMAD2/3). This event has been referred to as the canonical response to TGFβ. TGFβ also elicits other responses viewed as parallel events not directly connected to the SMAD activation, and thus referred to as noncanonical. A recognized response is the phosphorylation of the -activated kinase (TAK1/MAP3K), an upstream component of the mitogen-activated protein kinase (MAPK) cascade. We have now examined the relationship between these two effects of TGFβ1 at their earliest stages. The bulk of the studies were carried out with primary fibroblasts derived from the human cornea. The results' widespread relevance was confirmed in critical experiments with dermal-, and Tenon's capsule-derived fibroblasts. Cells were treated with kinase inhibitors or targeting siRNAs followed by induction by 2 ng/ml TGFβ1, and/or 10 ng/ml TNF-α. Cells were collected after 1 to 30 min for Western blot analysis and assayed for the accumulation of phosphorylated TAK1, ASK1, JNK1/2, p38, HPS27, MELK, SMAD2/3, and GAPDH. The effect of the kinase inhibitors on α-SMA expression and α-SMA stress fiber organization was also tested. For the immediate response to TGFβ1 we found that a) activation of the MAPK pathway was completed within 1 min after the addition of TGFβ1; b) phosphorylation of JNK1/2 was fully dependent on TAK1 and ASK1 activity, c) phosphorylation of MELK was fully dependent on JNK1/2 activity; d) phosphorylation of ASK1 depends on MELK activity, indicating the existence of an ASK1-MELK positive activation feedback loop; e) phosphorylation of SMAD2/3 started only after a 5 min period and reached a nadir after 10-15 min, f) the latter phosphorylation was fully blocked by inhibition of TAK1, ASK1, JNK1/2, and MELK, and siRNA-driven MELK downregulation; g) the inhibitors equally blocked the α-SMA protein expression, stress fiber development, and cell morphology changes at 72 h. These results demonstrate that the activation of the canonical pathway is fully subordinate to the activity of the MAPK pathway, challenging the concept of canonical and noncanonical TGFβ pathways and that SMAD2/3 activation is mediated by MELK, a kinase not previously associated with rapid pharmacological responses.

Indexed as

Leucine ZippersMyofibroblastsActinsHumansMitogen-Activated Protein KinasesPhosphorylationProtein Serine-Threonine KinasesSmad2 ProteinTransforming Growth Factor betaTransforming Growth Factor beta1ActinsMELK protein, humanMitogen-Activated Protein KinasesProtein Serine-Threonine KinasesSmad2 ProteinSMAD2 protein, humanTransforming Growth Factor betaTransforming Growth Factor beta1ASK1MAP kinases: TAK1MELKTGFβ1TGFβ canonicalTGFβ noncanonical

Identifiers

PMID37931692
PMCPMC10959399
OpenAlexW4388366342

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.